07:55 AM EDT, 06/11/2025 (MT Newswires) -- Novavax ( NVAX ) said Wednesday that results from initial cohort of its phase 3 trial showed its COVID-19-influenza combination and stand-alone flu vaccine candidates generated immune responses comparable to licensed products Nuvaxovid and Fluzone HD, respectively.

The trial showed that the both vaccines induced 2.4 to 5.7-fold increases in immune responses over baseline across the three flu strains H1N1, H3N2, B and SARS-CoV-2.

Novavax ( NVAX ) said over 98% of all adverse events were mild or moderate in severity.

The trial, which involved approximately 2,000 adults aged 65 and older, was not "adequately powered to demonstrate statistical significance," Novavax ( NVAX ) said.